References
- Solomon A, Weiss DT, Herrera GA. Light chain deposition disease In: Mehta J, Singhal S. Myeloma. London: Martin Dunitz; 2002. pp 507–518.
- Heilman HR, Velosa JA, Holley KE, . Long term follow-up and response to chemotherapy in patients with light chain deposition disease. Am J Kidney Dis 1992;20:34–41.
- Ronco P, Plaisier E, Mougenot B, . Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathology-driven therapy. Clin J Am Soc Nephrol 2006;1:1342–1350.
- Hassoun H, Flombaun C, D'Agati VD, . High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008;42:405–412.
- Weichman K, Dember LM, Prokaeva T, . Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339–343.
- Kastritis E, Migkou M, Gavriatopoulou M, . Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2008;94:300–302.
- Kaposztas Z, Kahan BD, Katz SM, . Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc 2009;41:4407–4410.
- Gasparetto C, Sanchorawala V, Snyder RM, . Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010;28(15 Suppl.): Abstract 8024.
- Gharwan H, Truica C. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 2011 Apr 9. [Epub ahead of print]